3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
34
Etoposide
25
Doxorubicin
20
Carboplatin
20
Vincristine
19
Isotretinoin
19
Topotecan
17
Temozolomide
17
Irinotecan
16
Filgrastim
16
Melphalan
15
Cisplatin
15
sargramostim
14
Radiotherapy
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
3-Iodobenzylguanidine
12
dinutuximab
11
Peripheral Blood Stem Cell Transplantation
11
naxitamab
9
Thiotepa
9
Magnetic Resonance Spectroscopy
9
humanized 3F8 anti-GD2 monoclonal antibody
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Ifosfamide
6
Antilymphocyte Serum
6
fludarabine phosphate
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroblastoma
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts